301 related articles for article (PubMed ID: 35673559)
21. Distinct Mutagenic Activity of APOBEC3G Cytidine Deaminase Identified in Bladder Cancer.
Caswell D; Swanton C
Cancer Res; 2023 Feb; 83(4):487-488. PubMed ID: 36789568
[TBL] [Abstract][Full Text] [Related]
22. A Robust Hypoxia Risk Score Predicts the Clinical Outcomes and Tumor Microenvironment Immune Characters in Bladder Cancer.
Liu Z; Tang Q; Qi T; Othmane B; Yang Z; Chen J; Hu J; Zu X
Front Immunol; 2021; 12():725223. PubMed ID: 34484235
[TBL] [Abstract][Full Text] [Related]
23. Construction and experimental validation of a B cell-related gene signature to predict the prognosis and immunotherapeutic sensitivity in bladder cancer.
Zhou R; Zhou J; Muhuitijiang B; Zeng X; Tan W
Aging (Albany NY); 2023 Jun; 15(12):5355-5380. PubMed ID: 37379131
[TBL] [Abstract][Full Text] [Related]
24. Whole-genome mapping of APOBEC mutagenesis in metastatic urothelial carcinoma identifies driver hotspot mutations and a novel mutational signature.
Nakauma-González JA; Rijnders M; Noordsij MTW; Martens JWM; van der Veldt AAM; Lolkema MPJ; Boormans JL; van de Werken HJG
Cell Genom; 2024 Apr; 4(4):100528. PubMed ID: 38552621
[TBL] [Abstract][Full Text] [Related]
25. IGFBP7 and the Tumor Immune Landscape: A Novel Target for Immunotherapy in Bladder Cancer.
Yi X; Zheng X; Xu H; Li J; Zhang T; Ge P; Liao D; Li H; Lyu X; Ai J
Front Immunol; 2022; 13():898493. PubMed ID: 35812369
[TBL] [Abstract][Full Text] [Related]
26. Identification of the role of MCM6 in bladder cancer prognosis, immunotherapy response, and in vitro experimental investigation using multi-omics analysis.
Wang J; Li X; Chen S; Cao J; Fan X; Wang H; Zhang X; Yang L
Life Sci; 2023 Dec; 335():122253. PubMed ID: 37951536
[TBL] [Abstract][Full Text] [Related]
27. A systems biology analysis of protein-protein interactions in the APOBEC family.
Wang Y; Chen G; Yang Y; Hu Z; Chen X
Life Sci; 2008 Oct; 83(15-16):521-30. PubMed ID: 18793652
[TBL] [Abstract][Full Text] [Related]
28. Identification of new driver and passenger mutations within APOBEC-induced hotspot mutations in bladder cancer.
Shi MJ; Meng XY; Fontugne J; Chen CL; Radvanyi F; Bernard-Pierrot I
Genome Med; 2020 Sep; 12(1):85. PubMed ID: 32988402
[TBL] [Abstract][Full Text] [Related]
29. The Cytidine Deaminase APOBEC3G Contributes to Cancer Mutagenesis and Clonal Evolution in Bladder Cancer.
Liu W; Newhall KP; Khani F; Barlow L; Nguyen D; Gu L; Eng K; Bhinder B; Uppal M; Récapet C; Sboner A; Ross SR; Elemento O; Chelico L; Faltas BM
Cancer Res; 2023 Feb; 83(4):506-520. PubMed ID: 36480186
[TBL] [Abstract][Full Text] [Related]
30. Identification of molecular subtypes based on liquid-liquid phase separation and cross-talk with immunological phenotype in bladder cancer.
Sun L; Liu XP; Yan X; Wu S; Tang X; Chen C; Li G; Hu H; Wang D; Li S
Front Immunol; 2022; 13():1059568. PubMed ID: 36518754
[TBL] [Abstract][Full Text] [Related]
31. Apolipoprotein B mRNA Editing Enzyme, Catalytic Polypeptide-Like Gene Expression, RNA Editing, and MicroRNAs Regulation.
Cao W; Wu W
Methods Mol Biol; 2018; 1699():75-81. PubMed ID: 29086369
[TBL] [Abstract][Full Text] [Related]
32. Mutagenesis of apobec-1, the catalytic subunit of the mammalian apolipoprotein B mRNA editing enzyme, reveals distinct domains that mediate cytosine nucleoside deaminase, RNA binding, and RNA editing activity.
MacGinnitie AJ; Anant S; Davidson NO
J Biol Chem; 1995 Jun; 270(24):14768-75. PubMed ID: 7782343
[TBL] [Abstract][Full Text] [Related]
33. Comprehensive Analyses Identify APOBEC3A as a Genomic Instability-Associated Immune Prognostic Biomarker in Ovarian Cancer.
Xu F; Liu T; Zhou Z; Zou C; Xu S
Front Immunol; 2021; 12():749369. PubMed ID: 34745121
[TBL] [Abstract][Full Text] [Related]
34. LDL receptor related protein 1 is an adverse prognostic biomarker that correlates with stromal remodeling and macrophages infiltration in bladder cancer.
Du Y; Liu Y; Cao J; Jiang X; Wang Y; Yu J; Wang B; Wang X; Xue B
Front Immunol; 2023; 14():1113756. PubMed ID: 37153545
[TBL] [Abstract][Full Text] [Related]
35. Scoring System Based on RNA Modification Writer-Related Genes to Predict Overall Survival and Therapeutic Response in Bladder Cancer.
Zhang P; Liu Z; Wang D; Li Y; Xing Y; Xiao Y
Front Immunol; 2021; 12():724541. PubMed ID: 34512654
[TBL] [Abstract][Full Text] [Related]
36. Apoptosis related genes mediated molecular subtypes depict the hallmarks of the tumor microenvironment and guide immunotherapy in bladder cancer.
Zhou L; Xu G; Huang F; Chen W; Zhang J; Tang Y
BMC Med Genomics; 2023 Apr; 16(1):88. PubMed ID: 37118734
[TBL] [Abstract][Full Text] [Related]
37. APOBEC Mutagenesis Inhibits Breast Cancer Growth through Induction of T cell-Mediated Antitumor Immune Responses.
DiMarco AV; Qin X; McKinney BJ; Garcia NMG; Van Alsten SC; Mendes EA; Force J; Hanks BA; Troester MA; Owzar K; Xie J; Alvarez JV
Cancer Immunol Res; 2022 Jan; 10(1):70-86. PubMed ID: 34795033
[TBL] [Abstract][Full Text] [Related]
38. Heat shock proteins stimulate APOBEC-3-mediated cytidine deamination in the hepatitis B virus.
Chen Z; Eggerman TL; Bocharov AV; Baranova IN; Vishnyakova TG; Kurlander R; Patterson AP
J Biol Chem; 2017 Aug; 292(32):13459-13479. PubMed ID: 28637869
[TBL] [Abstract][Full Text] [Related]
39. PD1
Wu C; Duan L; Li H; Liu X; Cai T; Yang Y; Yin Y; Chang W; Zhong L; Zhang L; Cheng Y; Qin H; Wen Z; Wang H; Mai S
Clin Transl Med; 2023 Jun; 13(6):e1303. PubMed ID: 37313656
[TBL] [Abstract][Full Text] [Related]
40. Identification of
Zhou R; Peng N; Li W
Front Immunol; 2022; 13():975503. PubMed ID: 36072584
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
